Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that its abstract titled "Virological Response, Safety, and Pharmacokinetic Profile Following Single- and Multiple-Dose Administration of ACH-0141625 Protease Inhibitor to Healthy Volunteers and HCV Genotype-1 Patients" has been accepted as a late breaking poster presentation at the International Liver Congress™ 2010 being held April 14-18 in Vienna, Austria.
Two additional abstracts on the compound's virology and hepatoselectivity titled Preclinical Antiviral Activity, Combination and Resistance of ACH-1625, A Potent HCV NS3 Protease Inhibitor, and Characterization of the Hepatoselective Distribution of ACH-1625, a Potent, Clinical Stage HCV NS3 Protease Inhibitor had previously been accepted for poster presentation.
Achillion's posters will be displayed from Thursday, April 15 at 8:00 a.m. through Saturday, April 17 at the end of the day's sessions.
The International Liver Congress 2010 by the European Association for the Study of the Liver (EASL) provides an opportunity for approximately 7,500 clinicians and scientists from around the world to receive the latest research, perspectives and treatments of liver disease from principal experts in the field.
New drug candidate reverses obesity in mice by transforming liver metabolism